PCN87 COST-EFFECTIVNESS ANALYSIS OF DABRAFENIB PLUS TRAMETINIB AS ADJUVANT TREATMENT FOR BRAF V600 MUTATION-POSITIVE MELANOMA AFTER SURGICAL RESECTION IN CANADA- A SOCIETAL PERSPECTIVE
Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.284
https://www.valueinhealthjournal.com/article/S1098-3015(19)32662-2/fulltext
Section Title :
Section Order :
10232
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32662-2&doi=10.1016/j.jval.2019.09.284